Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Ongoing Initiated Mar 15, 2016 (11 years ago)

Quelicin (Succinylcholine Chloride)

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for the lot number and/or expiration date to be faded or missing from the primary label on the glass vial.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Quelicin (Succinylcholine Chloride) Injection, USP 200 mg. (20 mg/mL), 10 mL Multiple-dose vial, packaged in 25 Unit vials per carton, Rx only, HOSPIRA, INC., LAKE FOREST, IL 60045 USA, NDC 0409-6629-02

Affected NDC 0409-6629-02

Compare with the code on your package — it is the most precise check available.

Drug: Succinylcholine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Quelicin
Succinylcholine Chloride
NDC 00409-6629
20 mg/mL Injection, Solution
Intramuscular|intravenous
Hospira, Inc. Rx
Recalling firm
Hospira Inc.
NDC code
0409-6629-02
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0836-2016 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm.

Other Succinylcholine recalls

See all
Class II · Moderate risk

Succinylcholine Chloride Injection

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 70710-1377-1 D-0623-2025

Other recalls by Hospira Inc.

All 2016 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016